WO2003087159A3 - Modulators of the notch signalling pathway and uses thereof in medical treatment - Google Patents
Modulators of the notch signalling pathway and uses thereof in medical treatment Download PDFInfo
- Publication number
- WO2003087159A3 WO2003087159A3 PCT/GB2003/001525 GB0301525W WO03087159A3 WO 2003087159 A3 WO2003087159 A3 WO 2003087159A3 GB 0301525 W GB0301525 W GB 0301525W WO 03087159 A3 WO03087159 A3 WO 03087159A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- modulators
- notch signalling
- medical treatment
- signalling pathway
- notch
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
Abstract
Priority Applications (25)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03746366A EP1492816A2 (en) | 2002-04-05 | 2003-04-04 | Modulators of the notch signalling pathway and uses thereof in medical treatment |
JP2003584114A JP2006506322A (en) | 2002-04-05 | 2003-04-04 | Internal medicine |
AU2003226537A AU2003226537A1 (en) | 2002-04-05 | 2003-04-04 | Modulators of the notch signalling pathway and uses thereof in medical treatment |
AU2003255735A AU2003255735A1 (en) | 2002-08-03 | 2003-08-01 | Conjugate of notch signalling pathway modulators and their use in medical treatment |
EP03766445A EP1525221A1 (en) | 2002-08-03 | 2003-08-01 | Conjugate of notch signalling pathway modulators and their use in medical treatment |
JP2005506075A JP2006513260A (en) | 2002-08-03 | 2003-08-01 | Complexes of Notch signaling pathway regulators and their use in drug therapy |
PCT/GB2003/003285 WO2004013179A1 (en) | 2002-08-03 | 2003-08-01 | Conjugate of notch signalling pathway modulators and their use in medical treatment |
JP2004571915A JP2006515177A (en) | 2002-09-10 | 2003-09-09 | Pharmaceutical composition comprising Notch ligand protein and medical treatment |
EP03748255A EP1537145A1 (en) | 2002-09-10 | 2003-09-09 | Pharmaceutical compositions and medical treatments comprising notch ligand proteins |
PCT/GB2003/003908 WO2004024764A1 (en) | 2002-09-10 | 2003-09-09 | Pharmaceutical composition and medical treatments comprising notch ligand proteins |
CA002497226A CA2497226A1 (en) | 2002-09-10 | 2003-09-09 | Pharmaceutical compositions and medical treatments comprising notch ligand proteins |
AU2003267563A AU2003267563A1 (en) | 2002-09-10 | 2003-09-09 | Pharmaceutical composition and medical treatments comprising notch ligand proteins |
PCT/GB2004/000046 WO2004060262A2 (en) | 2003-01-07 | 2004-01-07 | Modulators of notch signalling for use in immunotherpapy |
PCT/GB2004/000263 WO2004064863A1 (en) | 2003-01-23 | 2004-01-23 | Treatment of autoimmune diseases using an activator for the notch signaling pathway |
JP2006500232A JP2006517533A (en) | 2003-01-23 | 2004-01-23 | Treatment of autoimmune diseases using activators of the Notch signaling pathway |
EP04704657A EP1585543A1 (en) | 2003-01-23 | 2004-01-23 | Treatment of autoimmune diseases using an activator for the notch signaling pathway |
PCT/GB2004/001252 WO2004082710A1 (en) | 2003-03-21 | 2004-03-22 | Treatment of allergic diseases using a modulator of the notch signaling pathway |
AT04722319T ATE474593T1 (en) | 2003-03-21 | 2004-03-22 | TREATMENT OF ALLERGIC DISEASES USING A MODULATOR OF THE NOTCH SIGNALING PATHWAY |
EP04722319A EP1646400B1 (en) | 2003-03-21 | 2004-03-22 | Treatment of allergic diseases using a modulator of the notch signaling pathway |
US10/958,784 US20050220886A1 (en) | 2002-04-05 | 2004-10-05 | Modulators of the Notch signalling pathway and uses thereof in medical treatment |
US11/050,346 US20060002924A1 (en) | 2002-08-03 | 2005-02-03 | Conjugate of notch signalling pathway modulators and their use in medical treatment |
US11/078,735 US20050261477A1 (en) | 2002-09-10 | 2005-03-10 | Pharmaceutical compositions and medical treatments comprising notch ligand proteins |
US11/188,417 US20060204508A1 (en) | 2003-01-23 | 2005-07-25 | Treatment of autoimmune diseases using an activator for the notch signalling pathway |
US11/231,494 US20060205823A1 (en) | 2003-03-21 | 2005-09-21 | Treatment of allergic diseases using a modulator of the Notch signaling pathway |
US12/766,738 US20100303867A1 (en) | 2003-03-21 | 2010-04-23 | a composition comprising a notch ligand and an allergenb or allergen bystander antigen |
Applications Claiming Priority (18)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0207930A GB0207930D0 (en) | 2002-04-05 | 2002-04-05 | A method |
GB0207930.9 | 2002-04-05 | ||
GB0207929A GB0207929D0 (en) | 2002-04-05 | 2002-04-05 | A method |
GB0207929.1 | 2002-04-05 | ||
GB0212283A GB0212283D0 (en) | 2002-05-28 | 2002-05-28 | A method |
GB0212283.6 | 2002-05-28 | ||
GB0212282A GB0212282D0 (en) | 2002-05-28 | 2002-05-28 | A method |
GB0212282.8 | 2002-05-28 | ||
GBPCT/GB02/03397 | 2002-07-25 | ||
PCT/GB2002/003426 WO2003011317A1 (en) | 2001-07-25 | 2002-07-25 | Modulators of notch signalling for use in immunotherapy |
GBPCT/GB02/03426 | 2002-07-25 | ||
PCT/GB2002/003397 WO2003012441A1 (en) | 2001-07-25 | 2002-07-25 | Method for detecting modulators of notch signalling |
GB0220912A GB0220912D0 (en) | 2002-09-10 | 2002-09-10 | Medical treatment |
GB0220913.8 | 2002-09-10 | ||
GB0220913A GB0220913D0 (en) | 2002-09-10 | 2002-09-10 | Medical treatment |
GB0220912.0 | 2002-09-10 | ||
GB0300234.2 | 2003-01-07 | ||
GB0300234A GB0300234D0 (en) | 2003-01-07 | 2003-01-07 | Medical treatment |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/958,784 Continuation-In-Part US20050220886A1 (en) | 2002-04-05 | 2004-10-05 | Modulators of the Notch signalling pathway and uses thereof in medical treatment |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2003087159A2 WO2003087159A2 (en) | 2003-10-23 |
WO2003087159A3 true WO2003087159A3 (en) | 2004-02-05 |
WO2003087159A8 WO2003087159A8 (en) | 2005-05-12 |
Family
ID=34109266
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2003/001525 WO2003087159A2 (en) | 2002-04-05 | 2003-04-04 | Modulators of the notch signalling pathway and uses thereof in medical treatment |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1492816A2 (en) |
JP (1) | JP2006506322A (en) |
AU (1) | AU2003226537A1 (en) |
WO (1) | WO2003087159A2 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0220658D0 (en) * | 2002-09-05 | 2002-10-16 | Lorantis Ltd | Immunotherapy |
WO2004024764A1 (en) * | 2002-09-10 | 2004-03-25 | Lorantis Limited | Pharmaceutical composition and medical treatments comprising notch ligand proteins |
WO2004060262A2 (en) * | 2003-01-07 | 2004-07-22 | Lorantis Limited | Modulators of notch signalling for use in immunotherpapy |
GB0300428D0 (en) * | 2003-01-09 | 2003-02-05 | Lorantis Ltd | Medical treatment |
JP2006517533A (en) * | 2003-01-23 | 2006-07-27 | ロランティス リミテッド | Treatment of autoimmune diseases using activators of the Notch signaling pathway |
WO2004083372A2 (en) * | 2003-03-21 | 2004-09-30 | Lorantis Limited | Modulators of the notch signaling pathway immobilized on particles for modifying immune responses |
GB0307472D0 (en) * | 2003-04-01 | 2003-05-07 | Lorantis Ltd | Medical treatment |
WO2004099379A2 (en) | 2003-05-02 | 2004-11-18 | Health Research, Inc. | Use of jag2 expression in diagnosis of plasma cell disorders |
JP2007512348A (en) * | 2003-11-26 | 2007-05-17 | ヘルス リサーチ インコーポレイテッド | Use of Notch pathway interference agents for the treatment of plasma cells |
WO2005111072A2 (en) | 2004-04-29 | 2005-11-24 | The Trustees Of Columbia University In The City Of New York | Notch-based fusion proteins and uses thereof |
WO2007027226A2 (en) * | 2005-04-28 | 2007-03-08 | Board Of Regents, The University Of Texas System | Systems and methods for the production of differentiated cells |
US7906116B2 (en) | 2005-09-01 | 2011-03-15 | Parkash Gill | Methods for using and identifying modulators of Delta-like 4 |
US9127085B2 (en) * | 2007-08-23 | 2015-09-08 | The Trustees Of Columbia University In The City Of New York | Compositions of humanized notch fusion proteins and methods of treatment |
NZ591492A (en) | 2008-08-22 | 2012-10-26 | Univ Columbia | Human notch3 based fusion proteins as decoy inhibitors of notch3 signaling |
AR088048A1 (en) | 2011-10-04 | 2014-05-07 | Univ Columbia | NOTCH1 HUMAN LURE |
EP3752602A4 (en) * | 2018-02-14 | 2021-11-24 | Sunnybrook Research Institute | Method for generating cells of the t cell lineage |
US20210220434A1 (en) * | 2018-07-26 | 2021-07-22 | The Regents Of The University Of California | Treatment of Vascular Occlusion by Activation of Notch Signaling |
SG11202101455TA (en) * | 2018-08-28 | 2021-03-30 | Hutchinson Fred Cancer Res | Methods and compositions for adoptive t cell therapy incorporating induced notch signaling |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998020142A1 (en) * | 1996-11-07 | 1998-05-14 | Lorantis Limited | Notch |
EP0913404A1 (en) * | 1996-07-16 | 1999-05-06 | Asahi Kasei Kogyo Kabushiki Kaisha | Differentiation inhibitor |
WO2000025809A1 (en) * | 1998-10-30 | 2000-05-11 | Smith & Nephew Plc | Compositions comprising notch receptor manipulating agents |
WO2003041735A2 (en) * | 2001-11-14 | 2003-05-22 | Lorantis Limited | Composotion comprising inhibitors of the notch signalling pathway for the modulation of the immune system |
-
2003
- 2003-04-04 AU AU2003226537A patent/AU2003226537A1/en not_active Abandoned
- 2003-04-04 WO PCT/GB2003/001525 patent/WO2003087159A2/en active Application Filing
- 2003-04-04 JP JP2003584114A patent/JP2006506322A/en active Pending
- 2003-04-04 EP EP03746366A patent/EP1492816A2/en not_active Ceased
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0913404A1 (en) * | 1996-07-16 | 1999-05-06 | Asahi Kasei Kogyo Kabushiki Kaisha | Differentiation inhibitor |
WO1998020142A1 (en) * | 1996-11-07 | 1998-05-14 | Lorantis Limited | Notch |
WO2000025809A1 (en) * | 1998-10-30 | 2000-05-11 | Smith & Nephew Plc | Compositions comprising notch receptor manipulating agents |
WO2003041735A2 (en) * | 2001-11-14 | 2003-05-22 | Lorantis Limited | Composotion comprising inhibitors of the notch signalling pathway for the modulation of the immune system |
Non-Patent Citations (7)
Title |
---|
GRAY G E ET AL: "HUMAN LIGANDS OF THE NOTCH RECEPTOR", AMERICAN JOURNAL OF PATHOLOGY, PHILADELPHIA, PA, US, vol. 154, no. 3, March 1999 (1999-03-01), pages 785 - 794, XP000960906, ISSN: 0002-9440 * |
HICKS C ET AL: "A SECRETED DELTA1-FC FUSION PROTEIN FUNCTIONS BOTH AS AN ACTIVATOR AND INHIBITOR OF NOTCH1 SIGNALING", JOURNAL OF NEUROSCIENCE RESEARCH, WILEY-LISS, US, vol. 68, no. 6, 15 June 2002 (2002-06-15), pages 655 - 667, XP009013890, ISSN: 0360-4012 * |
JANG M-S ET AL: "NOTCH SIGNALING AS A TARGET IN MULTIMODALITY CANCER THERAPY", CURRENT OPINION IN MOLECULAR THERAPEUTICS, CURRENT DRUGS, LONDON,, GB, vol. 2, no. 1, February 2000 (2000-02-01), pages 55 - 65, XP009013844, ISSN: 1464-8431 * |
OSBORNE B ET AL: "Notch and the immune system", IMMUNITY, CELL PRESS, US, vol. 11, no. 6, December 1999 (1999-12-01), pages 653 - 663, XP002217474, ISSN: 1074-7613 * |
See also references of EP1492816A2 * |
SUN X ET AL: "SECRETED FORMS OF DELTA AND SERRATE DEFINE ANTAGONISTS OF NOTCH SIGNALING IN DROSOPHILA", DEVELOPMENT, COMPANY OF BIOLOGISTS, CAMBRIDGE,, GB, vol. 124, no. 17, 1997, pages 3439 - 3448, XP002925005, ISSN: 0950-1991 * |
ZLOBIN A ET AL: "TOWARD THE RATIONAL DESIGN OF CELL FATE MODIFIERS: NOTCH SIGNALING AS A TARGET FOR NOVEL BIOPHARMACEUTICALS", CURRENT PHARMACEUTICAL BIOTECHNOLOGY, BENTHAM SCIENCE PUBLISHERS, BOCA RATON,FL, US, vol. 1, no. 1, July 2000 (2000-07-01), pages 83 - 106, XP008004456, ISSN: 1389-2010 * |
Also Published As
Publication number | Publication date |
---|---|
AU2003226537A1 (en) | 2003-10-27 |
EP1492816A2 (en) | 2005-01-05 |
WO2003087159A8 (en) | 2005-05-12 |
AU2003226537A8 (en) | 2003-10-27 |
WO2003087159A2 (en) | 2003-10-23 |
JP2006506322A (en) | 2006-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003087159A3 (en) | Modulators of the notch signalling pathway and uses thereof in medical treatment | |
WO2005102335A3 (en) | Methods of treating sleep disorders | |
AU2003202196A1 (en) | Devices and methods for heart valve treatment | |
EP2266539A3 (en) | Methods of treatment using a gastric retained gabapentin dosage | |
WO2003062273A3 (en) | Modulator of the notch signalling pathway and use thereof in medical treatment | |
WO2003059372A3 (en) | Combined use of a glp-1 compound and a modulator of diabetic late complications | |
AU2003225160A1 (en) | "biosensor for dialysis therapy" | |
WO2007002390A3 (en) | Compositions and methods for modulation of smn2 splicing | |
WO2004072031A3 (en) | Phenylacetamides and their use as glucokinase modulators | |
AU2003300791A1 (en) | Combination therapy for the treatment of pain | |
WO2005105110A3 (en) | Doxepin analogs and methods of use thereof | |
WO2002084298A3 (en) | Medicaments which are modulators of hm74 and/or hm74a activity | |
WO2006041409A8 (en) | Medical solution, method for producing and use thereof | |
HK1075843A1 (en) | 1-phenyl-2-dimethylaminomethyl cyclohexane compounds used for the therapy of depressive symptoms, pain, and incontinence | |
EP1440691A3 (en) | Treatment of neurotic disorders | |
DK1397681T3 (en) | Method of identifying agents for the treatment of diabetes | |
AU2003255735A1 (en) | Conjugate of notch signalling pathway modulators and their use in medical treatment | |
WO2002039997A3 (en) | Ace-2 modulating compounds and use thereof | |
WO2003008637A3 (en) | Use of genotyping in the individualization of therapy | |
AU2003227944A1 (en) | Ddah modulators in the treatment of pain | |
WO2005007876A3 (en) | Modulation of interleukin-10 by dhea | |
WO2004093813A3 (en) | Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders | |
WO2001043697A3 (en) | Analogs of galanthamine and lycoramine as modulators of nicotinic receptors | |
WO2003070169A3 (en) | Aminodiphosphonate apolipoprotein e modulators | |
WO2001089558A3 (en) | Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10958784 Country of ref document: US Ref document number: 2003584114 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003746366 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003746366 Country of ref document: EP |
|
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i |
Free format text: IN PCT GAZETTE 43/2003 UNDER (30) REPLACE "PCT/GB2/03397 AND PCT/GB2/03426" BY "PCT/GB2002/003397 AND PCT/GB2002/003426" |